Exosomes Derived from Human Adipose Tissue-Derived Mesenchymal Stem Cells Alleviate Atopic Dermatitis

노바스템
2024-06-18
조회수 27

This study by Cho et al. explores the potential of exosomes derived from human adipose tissue-derived mesenchymal stem cells (ASC-exosomes) in treating atopic dermatitis (AD). Exosomes are nano-sized vesicles released by cells, capable of transferring lipids, proteins, and nucleic acids between cells, making them a promising cell-free therapeutic option. The study investigated the effects of ASC-exosomes in an AD mouse model induced by house dust mite antigens. The results showed that ASC-exosomes, administered either intravenously or subcutaneously, significantly reduced AD symptoms, including clinical scores, serum IgE levels, eosinophil counts, and mast cell infiltration. Additionally, ASC-exosomes decreased the mRNA expression of inflammatory cytokines such as IL-4, IL-23, IL-31, and TNF-α in AD skin lesions. These findings suggest that ASC-exosomes can be an effective cell-free therapy for AD.

Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by intense itching, dryness, and erythema. Current treatment options are limited and often associated with significant side effects. Therefore, there is a growing need for new, safe, and effective therapies. Exosomes, which are nano-sized extracellular vesicles released by various cells, have emerged as a promising alternative to cell-based therapies. They carry bioactive molecules that can modulate cellular functions and immune responses, potentially offering therapeutic benefits without the risks associated with cell transplantation.

This study by Cho et al. focuses on the therapeutic potential of exosomes derived from human adipose tissue-derived mesenchymal stem cells (ASC-exosomes) in treating AD. Exosomes from adipose tissue are particularly appealing due to their ease of isolation and high yield. The researchers aimed to evaluate whether ASC-exosomes could ameliorate AD symptoms in a mouse model.

The study used NC/Nga mice treated with house dust mite antigens to induce AD-like symptoms. The mice were then administered ASC-exosomes either intravenously (IV) or subcutaneously (SC) thrice a week for four weeks. Prednisolone was used as a positive control. The clinical severity of AD was assessed by measuring ear thickness, serum IgE levels, eosinophil counts, and the infiltration of inflammatory cells in skin lesions.

The results showed that ASC-exosomes significantly reduced AD symptoms in a dose-dependent manner. Both IV and SC administration of ASC-exosomes decreased ear thickness, clinical severity scores, and serum IgE levels. Histological analysis revealed that ASC-exosome treatment reduced the infiltration of mast cells and the number of CD86+ and CD206+ cells in skin lesions. These findings indicate that ASC-exosomes effectively suppress the inflammatory response in AD.

Additionally, the study investigated the impact of ASC-exosomes on the expression of pro-inflammatory cytokines. Quantitative real-time PCR (qRT-PCR) analysis showed that ASC-exosomes significantly reduced the mRNA levels of IL-4, IL-23, IL-31, and TNF-α in the skin lesions of AD mice. These cytokines are known to play critical roles in the pathogenesis of AD, and their downregulation correlates with the alleviation of AD symptoms.

The therapeutic effects of ASC-exosomes can be attributed to their ability to modulate immune responses and reduce inflammation. Exosomes carry various bioactive molecules, including anti-inflammatory cytokines and growth factors, which can influence the behavior of recipient cells and promote tissue repair.

The findings of this study are closely related to the therapeutic goals of Novastem's stem cell therapies, which aim to regenerate and repair damaged tissues. The immunomodulatory and anti-inflammatory properties of ASC-exosomes demonstrated in this study suggest that Novastem's treatments could offer similar benefits for conditions characterized by chronic inflammation and immune dysregulation, such as atopic dermatitis and other inflammatory skin diseases.


  • Mechanism of Action: ASC-exosomes modulate immune responses by reducing the levels of pro-inflammatory cytokines and inhibiting the infiltration of inflammatory cells in skin lesions.
  • Clinical Benefits: Administration of ASC-exosomes significantly reduces AD symptoms, including clinical severity, ear thickness, serum IgE levels, and inflammatory cell infiltration, in a mouse model of AD.
  • Potential for Broad Application: The success of ASC-exosomes in treating AD suggests their potential applicability to other chronic inflammatory and immune-mediated conditions, enhancing the scope of cell-free therapeutic strategies.




#AtopicDermatitis #Exosomes #MesenchymalStemCells #Immunomodulation #Inflammation #StemCellTherapy #CellFreeTherapy

0 0

THE POWER BRINGS YOU BACK



TEL. 031-741-0996

FAX. 031-741-0976

EMAIL. info@rev-med.co.kr

ADDRESS. 경기도 성남시 중원구 둔촌대로 464, 301, 306, 604, 605호(상대원동, 드림테크노)

THE POWER BRINGS YOU BACK


TEL. 031-741-0996  FAX. 031-741-0976  EMAIL. info@rev-med.co.kr

ADDRESS. 경기도 성남시 중원구 둔촌대로 464, 301, 306, 604, 605호(상대원동, 드림테크노)

법인명: (주)레보메드 | 사업자등록번호:120-87-36012